Loading...
Fueling an Epidemic: A Flood of 1.6 Billion Doses of Opioids into Missouri and the Need for Stronger DEA Enforcement
Senate Committee on Homeland Security and Governmental Affairs
Senate Committee on Homeland Security and Governmental Affairs
Abstract
At the request of Ranking Member Claire McCaskill, the Democratic staff of the Committee on Homeland Security and Governmental Affairs conducted an examination of the efforts McKesson, AmerisourceBergen, Cardinal Health, Mallinckrodt, and Endo have undertaken to meet their obligations under the CSA, as well as the suspicious order reports these companies have provided to DEA for Missouri orders between 2012 and 2017. The three major pharmaceutical distributors in the United States-McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. each recorded 2017 revenue in excess of $125 billion and ranked within the top 15 companies on the 2017 Fortune 500 list. Although unknown to many Americans, these companies play a critical role in preventing the diversion of opioid products from pharmacies and other customers to the black market.
Date
2018-07-12
Document Type
Senate Minority Staff Report
Serial Number
Document Length
36 pages
Congress
115
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
342: Substance, Alcohol and Drug Abuse, Treatment and Education
Related Hearings
• House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, hearing on "The Drug Enforcement Administration's Role in Combating the Opioid Epidemic," 115th Cong., H.Hrg. 115-110, (2018, March 20)
• Senate Committee on the Judiciary, hearing on "Oversight of the Ensuring Patient Access and Effective Drug Enforcement Act," 115th Cong., (2017, December 12)
• House Committee on Energy and Commerce, hearing on "Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives," 115th Cong., H.Hrg. 115-68, (2017, October 25)
• Senate Committee on the Judiciary, hearing on "Oversight of the Ensuring Patient Access and Effective Drug Enforcement Act," 115th Cong., (2017, December 12)
• House Committee on Energy and Commerce, hearing on "Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives," 115th Cong., H.Hrg. 115-68, (2017, October 25)